PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Gauges a company's environmental, social, and governance practices.
60.06
ESG score near Biotechnology median of 61.31. David Dodd would investigate if industry-standard ESG practices adequately address sector-specific risks.
57.55
Environmental score near Biotechnology median of 57.51. David Dodd would investigate if industry-standard environmental practices adequately address climate risks.
60.01
Social score 90-95% of Biotechnology median of 63.98. John Neff would demand higher returns to compensate for below-average stakeholder management.
62.62
Governance score near Biotechnology median of 62.68. David Dodd would investigate if industry-standard governance adequately protects shareholder interests.